Oncology
Medicines

Oncology Medicine Supply — Chemotherapy, Targeted Therapies & Named Patient

Access to oncology medicines is frequently complicated by shortage, lack of local registration, or the need for unlicensed alternatives. Euro Biom is positioned to bridge these gaps for NHS hospitals, international cancer centres, and humanitarian oncology programmes operating in low and middle-income countries.

Our oncology range covers the full spectrum of cancer therapeutics. Cytotoxic chemotherapy includes platinum compounds (carboplatin, cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), antimetabolites (methotrexate, capecitabine, fluorouracil, gemcitabine), anthracyclines (doxorubicin, epirubicin), alkylating agents (cyclophosphamide, ifosfamide, melphalan), and vinca alkaloids (vincristine, vinblastine, vinorelbine).

Our targeted therapy range includes kinase inhibitors (imatinib, erlotinib, gefitinib, osimertinib, ibrutinib, venetoclax), CDK 4/6 inhibitors (palbociclib, ribociclib), and monoclonal antibodies (rituximab, trastuzumab, bevacizumab, cetuximab). For hormone-sensitive cancers, we supply aromatase inhibitors (letrozole, anastrozole, exemestane), anti-androgens (bicalutamide, enzalutamide, abiraterone), and SERM/SERD agents (tamoxifen, fulvestrant).

Where standard licensed products are unavailable, we can supply under named patient, special import, or parallel import licence, ensuring your patients are not left without treatment. We work with oncology pharmacists and procurement teams across the NHS, GCC, and sub-Saharan Africa.